Looking to buy the report?


The acute lung injury refers to the clinical syndrome of acute respiratory failure because of acute inflammation, which causes disruption of the lung endothelial and epithelial barriers, adding substantial morbidity and mortality. The long-term quality of life is adversely affected. The research articles are majorly directed toward the identification of biomarkers involved within the inflammatory and coagulation cascades, for the early prediction of morbidity and mortality. Some of the clinical conditions with the development of acute lung injury are direct, such as pneumonia, pulmonary contusion, inhalational injury, indirect include sepsis, severe trauma, burns,  head injury, and drug overdose.

Several high-quality studies have provided the estimates of the incidence, however, they vary by age, race/ethnicity influences, lifestyle factors, and several other environmental factors in each geography. The companies, in the initial studies, have targeted capillary endothelium, alveolar epithelium, and both in certain cases. The usual route of delivery in clinical trials is intravenous and intrathecal. Some of the pipeline approaches involve blockade of inflammatory responses, inhibition, and neutralization.

Report Coverage

This report by Mordor Intelligence provides extensive insights into the current scenario and growth prospects of the market studied. Detailed graphical representations of the pipeline landscape, based on various phases and status of clinical trials across major regions of the world, are provided, with data obtained from multiple sources. The report also includes a list of key sponsors, having pipeline products for the concerned market.

Acute Lung Injury Clinical Trial Analysis, by Phase and Status

  • The clinical trial analysis for acute lung injury indicates that there are around XX number of trials under various phases.
  • Phase X trials accounted for the majority share.
  • The trial data analysis suggests a number of ongoing trials and the ones terminated. 

Acute Lung Injury Clinical Trials Analysis, by Geography

  • By geography, the scope of the report covers the regional assessment for clinical trials, globally. It covers concise information of registered clinical trials in different countries across several developed and emerging markets.
  • Some of the major factors globally relatable are the increasing incidence of accidental cases, heart-related disorders, such as heart failure, stroke, valvular heart disease, and non-cardiovascular events, like increasing diabetic cases. With that, the companies are creating more opportunities in improving the care and outcomes through increased usage of guideline-indicated treatments. There is an increasing demand for addressing the unmet needs of patients with lung injury, through evidence-based treatments.

Key Sponsors in Acute Lung Injury Clinical Trials

The report will cover analysis on trails and information on key sponsors, companies, and researchers.

Research Methodology

Our data collection team builds scientific research models, based on data sourced from various internal databases, primary and secondary researches, and our in-house team of research experts. The pipeline assessment reports are generated based on information procured from various stakeholders, such as sponsors, clinical trial organizations, pharmaceutical companies, government bodies, trade agencies, industry journals, scientific literature databases, investor reports, press release statements, and several other sources. The data generated using secondary research and primary research is validated through discussions with industry KOL’s and C-suite executives. The data presented in the reports is continuously updated to incorporate the most relevant and authentic information to our clients.

Reasons to buy the report

This report will help you understand

  • The number of clinical trials that are being conducted worldwide.
  • The key products under development (Phase I, Phase II, and Phase III).
  • The main areas of research under development (by product, mechanism of action, molecule, delivery, etc.).
  • The average recruitment size in trials.
  • Key deals between institutions and industries.
  • Gather insights on regional and country-level data.
  • Review of dormant and discontinued studies across the category.
  • Information on key sponsors and profiles.
  • Protocol and design comparisons, to generate the best solution for your product development strategy

1. Introduction

2. Research Methodology

3. Disease Epidemiology and Trends

4. Healthcare Expenditure and R&D Trends

5. Executive Summary

6. Clinical Trials Segmentation, by Phase

                6.1 Phase-III Product Candidates

                6.2 Phase-II Product Candidates

                6.3 Phase-I Product Candidates

7. Clinical Trials, Segmentation, by Status

                7.1 Suspended

                7.2 Terminated

                7.3 Withdrawn

                7.4 Ongoing

                7.5 Completed

                7.6 Other Statuses

8. Pipeline Therapeutic Assessment (Infographic Charts and Brief Description)

                8.1. By Clinical Phase and Molecule Type

                8.2. By Clinical Phase and Route of Administration

                8.3 By Sponsor/Collaborator/Institutions

                8.4 By Geography

9. Market Updates

10. Key Sponsor Profiles

11. Sources and Disclaimer

12. About Mordor Intelligence

Looking to buy the report?

Need a report that reflects how COVID-19 has impacted this market and its growth?

Looking to customize report?



By submitting, you confirm that you agree to our privacy policy